Compare FMBH & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMBH | DMRA |
|---|---|---|
| Founded | 1865 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1995 | 2020 |
| Metric | FMBH | DMRA |
|---|---|---|
| Price | $50.65 | $28.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $43.40 | $43.00 |
| AVG Volume (30 Days) | 93.3K | ★ 313.1K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | 16.06 | ★ 121.48 |
| EPS | ★ 2.10 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.30 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | $24.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.51 | $16.50 |
| 52 Week High | $53.36 | $34.89 |
| Indicator | FMBH | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 57.39 | 43.97 |
| Support Level | $50.49 | $28.16 |
| Resistance Level | $53.36 | $28.66 |
| Average True Range (ATR) | 0.91 | 1.48 |
| MACD | -0.10 | -0.40 |
| Stochastic Oscillator | 74.84 | 29.42 |
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.